Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis

Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy

(2015) John Slof et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice

(2014) Peter Flachenecker et al.   EUROPEAN NEUROLOGY

Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity

(2014) Peter Flachenecker et al.   EUROPEAN NEUROLOGY

Impact of Sativex®on quality of life and activities of daily living in patients with multiple sclerosis spasticity

(2014) Rafael Arroyo et al.   Journal of Comparative Effectiveness Research

Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life

(2013) P. Flachenecker et al.   ACTA NEUROLOGICA SCANDINAVICA

Costs and quality of life in multiple sclerosis patients with spasticity

(2013) J. Svensson et al.   ACTA NEUROLOGICA SCANDINAVICA

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain

(2013) Antonio García-Merino   Expert Review of Neurotherapeutics

Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study

(2013) Rafael Arroyo et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Spasticity in multiple sclerosis: results of a patient survey

(2013) C. Oreja-Guevara et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

(2012) Michael G. Serpell et al.   JOURNAL OF NEUROLOGY

Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis

(2012) Lanting Lu et al.   PHARMACOECONOMICS

Épidémiologie et évaluation clinique de la spasticité dans la sclérose en plaques

(2012) D. Bensmail et al.   REVUE NEUROLOGIQUE

Sativex® in multiple sclerosis spasticity: a cost–effectiveness model

(2012) John Slof et al.   Expert Review of Pharmacoeconomics & Outcomes Research

A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine

(2012) William G. Notcutt   Primary Health Care Research and Development

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study

(2011) Rafael Arroyo et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis

(2010) Howard L. Zwibel   ADVANCES IN THERAPY

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis

(2010) RBC Kavia et al.   Multiple Sclerosis Journal

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

(2008) John T. Farrar et al.   CLINICAL THERAPEUTICS